The Community Guide

- gsearch

Search Results

Narrow Results:

2021 1
2016 1

Panama 1

Journal Article 2

1 - 2 of 2 Results

Refine Results

Refine Results:

Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in Panama

CITE Title : Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in Panama Personal Author(s) : Rojas-Bonilla, Magda;Coulliette-Salmond, Angela;Belgasmi, Hanen;Wong, Kimberly;Sayyad, Leanna;Vega, Everardo;Grimoldi, Fabian;Oberste, Mark S.;Rüttimann, Ricardo; Published Date : July 13 2021 Source : Viruses. 2021; 13(7) URL : https://stacks.cdc.gov/view/cdc/108313 Rojas-Bonilla, Magda et al. (2021). Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in Panama. 13(7). Rojas-Bonilla, Magda et al. "Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in Panama" 13, no. 7 (2021) Rojas-Bonilla, Magda et al. "Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in Panama" vol. 13, no. 7, 2021 Export RIS Citation Information.

:

Rojas-Bonilla, Magda ;

Coulliette-Salmond, Angela

July 13 2021 | Viruses. 2021; 13(7)

:

Environmental surveillance was recommended for risk mitigation in a novel oral polio vaccine-2 (nOPV2) clinical trial (M5-ABMG) to monitor excretion, ...
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use

CITE Title : Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use Personal Author(s) : Duintjer Tebbens, Radboud J.;Hampton, Lee M.;Thompson, Kimberly M.; Published Date : Jun 01 2016 Source : BMC Infect Dis. 16. URL : https://stacks.cdc.gov/view/cdc/39946 Duintjer Tebbens, Radboud J. et al. (2016). Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. 16 Duintjer Tebbens, Radboud J. and Hampton, Lee M. and Thompson, Kimberly M. "Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use" 16 (2016) Duintjer Tebbens, Radboud J. et al. "Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use" vol. 16, 2016 Export RIS Citation Information.

:

Duintjer Tebbens, Radboud J. ;

Hampton, Lee M.

Jun 01 2016 | BMC Infect Dis. 16.

:

BackgroundThe endgame for polio eradication includes coordinated global cessation of oral poliovirus vaccine (OPV), starting with the cessation of vac...